Drug Profile
EO 1606
Latest Information Update: 13 May 2003
Price :
$50
*
At a glance
- Originator LEO Pharma
- Class Anti-inflammatories
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Dermatitis
Most Recent Events
- 13 May 2003 Discontinued - Phase-II for Dermatitis in Europe (unspecified route)